Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.

@article{McMurray2020EffectOD,
  title={Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.},
  author={John J. V. McMurray and David C. Wheeler and Bergur V Stefansson and Niels Jongs and Douwe Postmus and Ricardo Correa-Rotter and Glenn M. Chertow and Tom Greene and Claes Held and Fan-fan Hou and Johannes F E Mann and Peter Rossing and Carl David Sj{\"o}str{\"o}m and Robert D. Toto and Anna Maria Langkilde and Hiddo J Lambers Heerspink},
  journal={Circulation},
  year={2020}
}
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and kidney events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease. Methods: In the DAPA-CKD trial (Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease), 4304 participants with chronic kidney disease were randomized to dapagliflozin 10 mg… Expand
View on Wolters Kluwer
ahajournals.org
15 Citations
Background Citations
4

Figures and Tables from this paper

15 Citations

Citation Type

Citation Type

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
OBJECTIVES The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). BACKGROUND Patients with CKD,… Expand
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
TLDR
Baseline kidney function did not modify the benefits of dapagliflozin on morbidity and mortality in HFrEF, and dapgliflozar slowed the rate of decline in eGFR, including in patients without diabetes. Expand
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease.
  • A. Mottl
  • Medicine
  • The Journal of family practice
  • 2021
KEY TAKEAWAYS • Chronic kidney disease (CKD) is common, occurring in 1 of 7 adults in the United States. • 9 out of 10 adults with CKD are unaware of it. • People with CKD have the same risk for… Expand
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
TLDR
Dapagliflozin, a sodium‐glucose cotransporter‐2 inhibitor, has shown significant cardio‐ and renoprotective benefits in patients with type 2 diabetes, heart failure and chronic kidney disease, and may provide similar organ protection in high‐risk patients with COVID‐19. Expand
Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease
TLDR
Several outcome trials with SGLT-2 (sodium-glucose cotransporter-2) inhibitors and MRAs clearly suggest that these agents, apart from nephroprotection, offer important cardioprotection in this population of patients with CKD. Expand
Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease
TLDR
Following MI, adults with both diabetes and CKD had a higher risk for recurrent CVD events compared to those with prior CVD without diabetes or CKD. Expand
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review
TLDR
Risks of adverse clinical outcomes increase with CKD and albuminuria severity and are associated with substantial additional costs and resource utilisation, which should be a priority for healthcare providers to alleviate the burden of CV morbidity and its management on healthcare resources. Expand
Role of Uremic Toxins in Early Vascular Ageing and Calcification
TLDR
An update on pathophysiological processes and mediators underlying VC and EVA induced by uremic toxins is presented, and their clinical impact, and possible therapeutic targets aiming at preventing or ameliorating the harmful effects of uRemic toxins on the vasculature are discussed. Expand
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus
TLDR
Dapagliflozin and ticagrelor attenuated the progression of diabetic nephropathy in BTBR ob/ob mice with additive effects of the combination. Expand
The Johns Hopkins Ciccarone Center's expanded ‘ABC's approach to highlight 2020 updates in cardiovascular disease prevention
TLDR
The Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease expanded ‘ABC's approach is used to highlight key findings in Preventive Cardiology from 2020 and further emphasize the importance of cardiovascular prevention. Expand
...
1
2
...

References

SHOWING 1-10 OF 28 REFERENCES
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in anLower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rates of hospitalizationFor heart failure. Expand
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. Expand
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
  • H. Heerspink, B. Stefansson, +56 authors Pham Van Bui
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2020
TLDR
DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes. Expand
Dapagliflozin in Patients with Chronic Kidney Disease.
TLDR
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo. Expand
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
  • D. Wheeler, B. Stefansson, +30 authors H. Heerspink
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2020
TLDR
The DAPA-CKD trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2–4 and increased albuminuria, with and without type 2 diabetes. Expand
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
TLDR
The epidemiology and pathophysiological mechanisms of cardiovascular risk in patients with chronic kidney disease are discussed, and methods of prevention are discussed. Expand
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
TLDR
SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atheroscerotic cardiovascular disease, however, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerosis or a history of heart failure. Expand
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
TLDR
Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes. Expand
Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease
TLDR
Although current treatment of patients with CKD includes management of traditional and nontraditional risk factors, the value of modifying some nontraditionally risk factors remains unclear. Expand
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. Expand
...
1
2
3
...